Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy

References

• Nebbioso M, Iannaccone A, Duse M, Aventaggiato M, Bruscolini A, ZicariAM Vascular Endothelial Growth Factor (VEGF) serological and lacrimal signaling in patients affected by Vernal Keratoconjunctivitis (VKC). J Ophthalmol. 2018;2018:1–6. doi: 10.1155/2018/3850172.
   Web of Science ®Google Scholar
• Bremond-Gignac D, Donadieu J, Leonardi A Prevalence of vernal keratoconjunctivitis: a rare disease? Br J Ophthalmol. 2008;92(8):1097–1102. doi: 10.1136/bjo.2007.117812.
   PubMed Web of Science ®Google Scholar
• Bonini S, Sacchetti M, Mantelli F, Lambiase A Clinical grading of vernal keratoconjunctivitis. Curr Opin Allergy Clin Immunol. 2007;7(5):436–441. doi: 10.1097/ACI.0b013e3282efb726.
   PubMed Web of Science ®Google Scholar
• Nebbioso M, Zicari AM, Lollobrigida V, Marenco M, Duse M Assessment of corneal alterations by confocal microscopy in vernal keratoconjunctivitis. Semin Ophthalmol. 2015;30(1):40–43. doi: 10.3109/08820538.2013.821508.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Busca F, Motterle L, et al. Case series of 406 vernal keratoconjunctivitis patients: a demographic and epidemiological study. Acta Ophthalmol Scand. 2006;84(3):406–410. doi: 10.1111/j.1600-0420.2005.00622.x.
   PubMedGoogle Scholar
• Bonini S, Bonini S, Lambiase A, et al. Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup. Ophthalmology. 2000;107(6):1157–1163. doi: 10.1016/S0161-6420(00)00092-0.
   PubMed Web of Science ®Google Scholar
• Kosrirukvongs P, Vichyanond P, Wongsawad W Vernal keratoconjunctivitis in Thailand. Asian Pac J Allergy Immunol. 2003;21(1):25–30.
   PubMed Web of Science ®Google Scholar
• Zicari AM, Zicari A, Nebbioso M et al. High-mobility group box-1 (HMGB-1) and serum soluble receptor for advanced glycation end products (sRAGE) in children affected by vernal keratoconjunctivitis. Pediatr Allergy Immunol. 2014;25(1):57–63. doi: 10.1111/pai.12142.
   PubMed Web of Science ®Google Scholar
• Bozkurt B, Artac H, Arslan N, et al. Systemic atopy and immunoglobulin deficiency in Turkish patients with vernal keratoconjunctivitis. Ocul Immunol Inflamm. 2013;21(1):28–33. doi: 10.3109/09273948.2012.723110.
   PubMed Web of Science ®Google Scholar
• Leonardi A, DeFranchis G, Zancanaro F et al. Identification of local Th2 and Th0 lymphocytes in vernal conjunctivitis by cytokine flow cytometry. Invest Ophthalmol Vis Sci. 1999;40(12):3036–3040.
   PubMed Web of Science ®Google Scholar
• Micera A, Di Zazzo A, Esposito G, Sgrulletta R, Calder VL, Bonini S. Quiescent and active tear protein profiles to predict vernal keratoconjunctivitis reactivation. Biomed Res Int. 2016; 2016:9672082. doi:10.1155/2016/9672082.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Di Stefano A, Motterle L, Zavan B, Abatangelo G, Brun P Transforming growth factor-β/Smad – signalling pathway and conjunctival remodelling in vernal keratoconjunctivitis. Clin Exp Allergy. 2011;41(1):52–60. doi: 10.1111/j.1365-2222.2010.03626.x.
   PubMed Web of Science ®Google Scholar
• Sacchetti M, Bruscolini A, Abicca I, et al. Current and emerging treatment options for vernal keratoconjunctivitis, Expert Opin Orphan Drugs. 2017;5:4, 343–353. doi: 10.1080/21678707.2017.1300524.
   Web of Science ®Google Scholar
• Lambiase A, Micera A, Sacchetti M, Mantelli F, Bonini S Toll-like receptors in ocular surface diseases: overview and new findings. Clin Sci (Lond). 2011;120(10):441–450. doi: 10.1042/CS20100425.
   PubMed Web of Science ®Google Scholar
• Lambiase A, Normando EM, Vitiello L, et al. Natural killer cells in vernal keratoconjunctivitis. Mol Vis. 2007;13:1562–1567.
   PubMed Web of Science ®Google Scholar
• Zicari AM, Mora B, Lollobrigida V, et al. Immunogenetic investigation in vernal keratoconjunctivitis. Pediatr Allergy Immunol. 2014;25(5):508–510. doi: 10.1111/pai.12231.
   Web of Science ®Google Scholar
• Bonini S, Lambiase A, Schiavone M, Centofanti M, Palma LA, Bonini S Estrogen and progesterone receptors in vernal keratoconjunctivitis. Ophthalmology. 1995;102(9):1374–1379. doi:10.1016/S0161-6420(95)30861-5.
   PubMed Web of Science ®Google Scholar
• Sacchetti M, Lambiase A, Moretti C, Mantelli F, Bonini S Sex hormones in allergic conjunctivitis: altered levels of circulating androgens and estrogens in children and adolescents with vernal keratoconjunctivitis. J Immunol Res. 2015;2015:945317. doi: 10.1155/2015/945317.
   Web of Science ®Google Scholar
• Zicari AM, Cafarotti A, Occasi F et al. Vitamin D levels in children affected by vernal keratoconjunctivitis. Curr Med Res Opin. 2017;33(2):269–274. doi: 10.1080/03007995.2016.1254602.
   PubMed Web of Science ®Google Scholar
• Bantz SK, Zhu Z, Zheng T The role of vitamin D in pediatric asthma. Ann Pediatr Child Health. 2015;3(1):1032.
   PubMedGoogle Scholar
• McFadden JP, Thyssen JP, Basketter DA, Puangpet P, Kimber I T helper cell 2 immune skewing in pregnancy/early life: chemical exposure and the development of atopic disease and allergy. Br J Dermatol 2015;172(3):584–591. doi: 10.1111/bjd.13497.
   PubMed Web of Science ®Google Scholar
• Zicari AM, Nebbioso M, Zicari A, et al. Serum levels of IL-17 in patients with vernal keratoconjunctivitis: a preliminary report. Eur Rev Med Pharmacol Sci. 2013;17(9):1242–1244.
   PubMed Web of Science ®Google Scholar
• Kim J, Kang S, Kim J, Kwon G, Koo S Elevated levels of T helper 17 cells are associated with disease activity in patients with rheumatoid arthritis. Ann Lab Med. 2012;33(1):52–59. doi:10.3343/alm.2013.33.1.52.
   Web of Science ®Google Scholar
• Zicari AM, Nebbioso M, Lollobrigida V et al. Vernal keratoconjunctivitis: atopy and autoimmunity. Eur Rev Med Pharmacol Sci. 2013;17(10):1419–1423.
   PubMed Web of Science ®Google Scholar
• Nebbioso M, Zicari AM, Celani C, Lollobrigida V, Grenga R, Duse M Pathogenesis of vernal keratoconjunctivitis and associated factors. Semin Ophthalmol. 2015; 30 (5–6): 340–344. doi: 10.3109/08820538.2013.874483.
   PubMed Web of Science ®Google Scholar
• Malagola R, Arrico L, Migliorini R, D’Ambrosio EM, Grenga R Ocular traumatology in children. A retrospective study. G Chir. 2012; 33 (11–12): 423–428.
   Google Scholar
• Gokhale NS Systematic approach to managing vernal keratoconjunctivitis in clinical practice: severity grading system and a treatment algorithm. Indian J Ophthalmol. 2016;64(2):145–148. doi:10.4103/0301-4738.179727.
   PubMed Web of Science ®Google Scholar
• Gokhale NS, Samant R, Sharma V Oral cyclosporine therapy for refractory severe vernal keratoconjunctivitis. Indian J Ophthalmol. 2012;60:220–223. doi: 10.4103/0301-4738.95878.
   PubMed Web of Science ®Google Scholar
• Sacchetti M, Lambiase A, Mantelli F, Deligianni V, Leonardi A, Bonini S Tailored approach to the treatment of vernal keratoconjunctivitis. Ophthalmology. 2010;117(7):1294–1299. doi: 10.1016/j.ophtha.2009.11.043.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Lazzarini D, La Gloria Valerio A, Scalora T, Fregona I Corneal staining patterns in vernal keratoconjunctivitis: the new VKC-CLEK scoring scale. Br J Ophthalmology. 2018;102:1448–1453. doi: 10.1136/bjophthalmol-2017-311171.
   Web of Science ®Google Scholar
• Mantelli F, Santos MS, Petitti T, et al. Systematic review and meta analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis. Br J Ophthalmol. 2007;91(12):1656–1661. doi: 10.1136/bjo.2007.122044.
   PubMed Web of Science ®Google Scholar
• Labcharoenwongs P, Jirapongsananuruk O, Visitsunthorn N, Kosrirukvongs P, Saengin P, Vichyanond P A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children. Asian Pac J Allergy Immunol. 2012;30:177–184.
   PubMed Web of Science ®Google Scholar
• Borel JF, Feurer C, Magnee C, et al. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology. 1977;32:1017–1025.
   PubMed Web of Science ®Google Scholar
• Borel JF, Feurer C, Gubler HU, et al. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions. 1976;6:468–475. doi:10.1007/BF01973261
   PubMedGoogle Scholar
• Calne RY Immunosuppression for organ grafting – observations on cyclosporin A. Immunol Rev. 1979;46:113–124.
   PubMed Web of Science ®Google Scholar
• Ahern MJ, Harrison W, Hollingsworth P, Bradley J, Laing B, Bauliss C A randomised double-blind trial of cyclosporin and azathioprine in refractory rheumatoid arthritis. Aust N Z J Med. 1991;21(6):844–849.
   Google Scholar
• Amor B, Dougados M Cyclosporine: therapeutic effects in rheumatic diseases. Transplant Proc. 1988;20(3 Suppl 4):218–223.
   Web of Science ®Google Scholar
• Laupacis A, Keown PA, Ulan RA, McKenzie N, Stiller CR, Cyclosporin A. A powerful immunosoprressant. Can Med Assoc J. 1982;126(9):1041–1046.
   PubMed Web of Science ®Google Scholar
• Halloran F, Madrenas J The mechanism of action of cyclosporine: a perspective for the 90’s. Clin Biochem. 1991;24:3–7 doi: 10.1016/0009-9120(91)90063-K.
   PubMed Web of Science ®Google Scholar
• Liu J FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. Trends Pharmacol Sci. 1993;14(5):182–188. doi: 10.1016/0165-6147(93)90206-Y.
   Web of Science ®Google Scholar
• Ho S, Clipstone N, Timmermann L, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol. 1996; 80 (3 Pt 2): S40–S5.
   PubMedGoogle Scholar
• Cocco L, Rubbini S, Manzoli L, et al. Inositides in the nucleus: presence and characterisation of the isozymes of phospholipasebeta family in NIH 3T3 cells. Biochim Biophys Acta 1999;1438:295–299. doi:10.1016/s1388-1981(99)00061-x
   PubMed Web of Science ®Google Scholar
• Schreiber SL, Crabtree GR The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992;13(4):136–142 doi: 10.1016/0167-5699(92)90111-J.
   PubMedGoogle Scholar
• Coster DJ, Shepherd WF, Fook TC, Rice NS, Jones BR Prolonged survival of corneal allografts in rabbits treated with cyclosporin A. Lancet 1979;2:68–89.
   Web of Science ®Google Scholar
• Hunter PA, Wilhelmus KR, Rice NS, Jones BR Cyclosporin A applied topically to the recipient eye inhibits corneal graft rejection. Clin Exp Immunol 1981;45:173–177.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. [ updated April 08, 2005]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-023_Restasis.cfm. Accessed March 29, 2019.
   Google Scholar
• Donnenfeld E, Pflugfelder SC Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol 2009;54:321–338. doi: 10.1016/j.survophthal.2009.02.002
   PubMed Web of Science ®Google Scholar
• Gupta V, Sahu PK Topical cyclosporin A in the management of vernal keratoconjunctivitis. Eye. 2001;15(Pt 1):39–41. doi: 10.1038/eye.2001.10.
   PubMed Web of Science ®Google Scholar
• Levy O, Labbé A, Borderie V, Laroche L, Bouheraoua N La ciclosporine topique en ophtalmologie: farmacologie et indications thérapeutiques. J Fr Ophtalmol. 2016;39(3):292–307. doi:10.1016/j.jfo.2015.11.008
   PubMed Web of Science ®Google Scholar
• Mihatsch MJ, Kyo M, Morozumi K, Yamaguchi Y, Nickeleit V, Ryffel B The side-effects of ciclosporine-A and tacrolimus. Clin.Nephrol. 1998;49:356–363.
   PubMed Web of Science ®Google Scholar
• Ganesan V, Milford DV, Taylo CM, Hulton SA, Parvaresh S, Ramani P Cyclosporin-related nephrotoxicity in children with nephrotic syndrome. Pediatr Nephrol 2002;17:225–226. doi: 10.1007/s00467-001-0810-1.
   PubMed Web of Science ®Google Scholar
• Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm. 2003;56:307–318. doi: 10.1016/S0939-6411(03)00138-3.
   PubMed Web of Science ®Google Scholar
• Tang-Liu DD, Acheampong A Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye. Clin Pharmacokinet. 2005;44:247–261. doi: 10.2165/00003088-200544030-00003.
   PubMed Web of Science ®Google Scholar
• Baiza-Duran LM, González-Villegas AC, Contreras-Rubio Y, et al. Safety and efficacy of topical 0.1% and 0.05% cyclosporine A in an aqueous solution in steroid-dependent vernal keratoconjunctivitis in a population of Mexican children. J Clin Exp Ophthalmol. 2010;1:115. doi:10.4172/2155-9570.1000115.
   Google Scholar
• Lallemand F, Schmitt M, Bourges JL, Gurny R, Benita S, Garrigue JS.Cyclosporine A delivery to the eye: a comprehensive review of academic and industrial efforts. Eur J Pharm Biopharm. 2017;117:14–28. doi: 10.1016/j.ejpb.2017.03.006.
   PubMed Web of Science ®Google Scholar
• Kauss Hornecker M, Charles Weber S, Brandely Piat M-L, Darrodes M, Jomaa K, Chast F Cyclosporine eye drops: a 4-year retrospective study (2009–2013). J Fr Ophtalmol 2015;38:700–708. doi: 10.1016/j.jfo.2015.02.008.
   PubMed Web of Science ®Google Scholar
• Labbé A, Baudouin C, Ismail D et al. Pan-European survey of the topical ocular use of cyclosporine A. J Fr Ophtalmol. 2017;40(3):187–195. doi: 10.1016/j.jfo.2016.12.004.
   Web of Science ®Google Scholar
• Esposito S, Fior G, Mori A, Osnaghi S, Ghiglioni D. An update on the therapeutic approach to vernal keratoconjunctivitis. Pediatric Drugs. 2016;18(5):347–355. doi: 10.1007/s40272-016-0185-1.
   Web of Science ®Google Scholar
• Leonardi A Management of vernal keratoconjunctivitis. Ophthalmol Ther. 2013;2(2):73–88. doi:10.1007/s40123-013-0019-y.
   PubMedGoogle Scholar
• Singhal D, Sahay P, Maharana PK, Raj N, Sharma N, Titiyal JS Vernal keratoconjunctivitis. Surv Ophthalmol. 2018;12. pii: S0039–6257(18)30152–8. doi: 10.1016/j.survophthal.2018.12.001.
   Web of Science ®Google Scholar
• Uchio E, Kimura R, Migita H, Kozawa M, Kadonosono K Demographic aspects of allergic ocular diseases and evaluation of new criteria for clinical assessment of ocular allergy. Graefes Arch Clin Exp Ophthalmol. 2008;246(2):291–296. doi: 10.1007/s00417-007-0697-z.
   PubMed Web of Science ®Google Scholar
• Ebihara N, Ohashi Y, Uchio EA et al. large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther. 2009;25(4):365–372. doi: 10.1089/jop.2008.0103.
   PubMed Web of Science ®Google Scholar
• Quintana-Hau JD, Cruz-Olmos E, López-Sánchez MI, et al. Characterization of the novel ophthalmic drug carrier sophisen in two of its derivatives: 3A ofteno and modusik-A ofteno. Drug Dev Ind Pharm. 2005;31(3):263–269. doi: 10.1081/DDC-52058.
   PubMed Web of Science ®Google Scholar
• Takamura E, Uchio E, Ebihara N, et al. A prospective, observational, all-prescribed-patients study of cyclosporine 0.1% ophthalmic solution in the treatment of vernal keratoconjunctivitis. Nihon Ganka Gakkai Zasshi. 2011;115(6):508–515.
   Google Scholar
• Bron AJ, Evans VE, Smith JA Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003;22(7):640–650.
   PubMed Web of Science ®Google Scholar
• Sacchetti M, Baiardini I, Chini L, Moschese V, Bruscolini A, Lambiase A Development and preliminary validation of a new screening questionnaire for identifying atopic children. Pediatric Health Med Ther. 2017;8:99–105. doi:10.2147/PHMT.S142271.
   Web of Science ®Google Scholar
• Leonardi A, Doan S, Amrane M, et al. A randomized, controlled trial of cyclosporine A cationic emulsion in pediatric vernal keratoconjunctivitis: the VEKTIS study. Ophthalmology. 2018;27. pii: S0161-6420(18)31697-X. doi: 10.1016/j.ophtha.2018.12.027.
   Web of Science ®Google Scholar
• Kiliç A, Gürler B Topical 2% cyclosporine A in preservative-free artificial tears for the treatment of vernal keratoconjunctivitis. Can J Ophthalmol. 2006;41(6):693–698. doi:10.3129/i06-061.
   PubMed Web of Science ®Google Scholar
• Pucci N, Novembre E, Cianferoni A, et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol. 2002;89(3):298–303. doi:10.1016/S1081-1206(10)61958-8.
   PubMed Web of Science ®Google Scholar
• Spadavecchia L, Fanelli P, Tesse R et al. Efficacy of 1.25% and 1% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood. Pediatr Allergy Immunol. 2006;17(7):527–532. doi: 10.1111/j.1399-3038.2006.00427.x.
   PubMed Web of Science ®Google Scholar
• Lambiase A, Leonardi A, Sacchetti M, et al. Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study. J Allergy Clin Immunol. 2011;128(4):896–897. doi: 10.1016/j.jaci.2011.07.004.
   PubMed Web of Science ®Google Scholar
• Keklikci U, Dursun B, Cingu AK Topical cyclosporine a 0.05% eyedrops in the treatment of vernal keratoconjunctivitis-randomized placebo-controlled trial. Adv Clin Exp Med. 2014;23(3):455–461. doi:10.17219/acem/37145
   PubMed Web of Science ®Google Scholar
• Daniell M, Constantinou M, Vu HT, Taylor HR Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol. 2006;90(4):461–464. doi:10.1136/bjo.2005.082461.
   PubMed Web of Science ®Google Scholar
• Pescosolido N, Barbato A, Pascarella A, Giannotti R, Genzano M, Nebbioso M Role of protease-inhibitors in ocular diseases. Molecules. 2014;19(12):20557–20569. doi:10.3390/molecules191220557
   Web of Science ®Google Scholar
• Nebbioso M, Sacchetti M, Bianchi G, et al. Tear ferning test and pathological effects on ocular surface before and after topical cyclosporine in vernal keratoconjunctivitis patients. J Ophthalmol. 2018;2018:1061276. doi:10.1155/2018/1061276.
   Web of Science ®Google Scholar
• Sacchetti M, Macchi I, Tiezzi A, La Cava M, Massaro-Giordano G, Lambiase A Pathophysiology of corneal dystrophies: from cellular genetic alteration to clinical findings. J Cell Physiol. 2016;231(2):261–269. doi: 10.1002/jcp.25082
   PubMed Web of Science ®Google Scholar
• Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapyreport. Ocul Surf. 2017;15(3):575–628. doi: 10.1016/j.jtos.2017.05.006.
   PubMed Web of Science ®Google Scholar